

## Curriculum Vitae

**Name:** Marianne J. Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP®

### Education:

Doctorate of Nursing Practice	MGH Institute of Health Professions Boston, Massachusetts	2014
Acute Care Nurse Practitioner	Yale School of Nursing New Haven, Connecticut	2000
Masters of Science in Nursing	Yale School of Nursing New Haven, Connecticut	1987
Bachelor of Science in Nursing	Russell Sage College Troy, New York	1983

### DNP Project:

Davies, Marianne (2014)  
Title: Development of a Journal Club Training Workbook to Enhance Competence & Confidence of Journal Club Facilitators  
MGH Institute of Health Professions  
Chair: Dr. Laurie Lauzon Clabo, PhD, RN,  
Dean of the School of Nursing

### Post Graduate Training:

2014	Certificate of Advanced Study Teaching & Learning	MGH Institute of Health Professions Boston, Massachusetts
2014	A Systems Approach to Assessment In Health Professions Education	Harvard-Macy Programs Boston, Massachusetts
2013	Simulation Instructor Certificate The Institute for Medical Simulation	Harvard-MIT-Macy Program Boston, Massachusetts

### Licenses, Certifications:

2011-Present	Advanced Oncology Certified Nurse Practitioner® Oncology Nursing Certification Corporation Oncology Nursing Society
2005-2006	Advanced Practice Registered Nurse 312603 State of Nevada

## Curriculum Vitae

- 2003-2011 Advance Oncology Certified Nurse®  
Oncology Nursing Certification Corporation  
Oncology Nursing Society
- 2001-Present Acute Care Nurse Practitioner  
Certification #: 0355675-28  
American Nurses Credentialing Center
- 1987-Present Clinical Nurse Specialist in Adult Health  
Certification # 339690-05  
American Nurse Credentialing Center
- 1998-Present Advanced Practice Registered Nurse 002166  
State of Connecticut
- 1998-2003 Oncology Certified Nurse®  
Oncology Nursing Certification Corporation  
Oncology Nursing Society
- 1983-Present Registered Nurse E46516  
State of Connecticut

### **Employment:**

- 2020-present Oncology Nurse Practitioner, Section of Medical Oncology  
Smilow Cancer Hospital at Yale-New Haven Hospital  
New Haven, CT
- 2020-present Coordinator Oncology Nurse Practitioner Concentration & Lecturer  
Yale School of Nursing  
West Haven, CT
- 2019-2020 Associate Professor  
Acute Care, DNP  
Yale School of Nursing  
New Haven, CT
- 2015-2019 Assistant Professor  
Acute Care, FNP, DNP  
Yale School of Nursing  
New Haven, CT.
- 2005-2020 Oncology Nurse Practitioner, Section of Medical Oncology  
Smilow Cancer Hospital at Yale-New Haven Hospital  
Yale School of Medicine  
New Haven, CT.
- 2001-2014 Lecturer: Acute Care & FNP, Assistant Clinical Professor  
Yale School of Nursing  
New Haven, CT.

## Curriculum Vitae

2004-2005	Director of Patient and Nursing Services Technical Director Clinical Trials Office Nevada Cancer Institute Las Vegas, NV.
2002-2004	Oncology Nurse Practitioner (ONP), Coordinator: ONP's Section of Medical Oncology Yale School of Medicine New Haven, CT.
2000-2002	Oncology Nurse Practitioner, Section of Medical Oncology Yale School of Medicine New Haven, CT.
1999-2000	Clinical Nurse Specialist, Lung Cancer/Clinical Trails Symptom Management Clinic Yale School of Medicine New Haven, CT.
1998-1999	Staff Nurse, Medical Oncology Yale New Haven Hospital New Haven, CT.
1991-1998	Staff Nurse, Bone Marrow Transplant Unit Yale New Haven Hospital New Haven, CT.
1987-1989	Clinical Nurse Specialist, Medical Surgical Nursing Lawrence & Memorial Hospital New London, CT
1989 – 1991 1983 – 1987	Staff Nurse, Medical Oncology Inpatient Unit Yale-New Haven Hospital New Haven, CT
1979 – 1983	Teaching Associate Department of Mental Retardation State of Connecticut Danbury, CT

### Awards & Honors

2019	Yale New Haven Hospital Advance Practice Provider Publishing Award
2015	Dove Medical Press Video Award, “New modalities of cancer treatment for NSCLC: focus on immunotherapy”
2015	Nightingale Award for Excellence in Nursing. Visiting Nurse Association of South Central Connecticut
2012	Ruth McCorkle Oncology Advanced Practice Provider: Yale Cancer Center.
2012/2011	Yale-New Haven Hospital Medical Staff Patient Experience Recognition
1987-current	Sigma Theta Tau, National Honor Society of Nursing

1983 Cogswell Award, Outstanding Student Leadership and Community Involvement  
Russell-Sage College, Troy, NY

## Publications

### Peer-Reviewed Publications:

- Hakim, H, alexander, C., Rudell, E., Ingram, M., Peterson, P., Agrawal, T., Davies, M., Adelson, K., Herbst, R. & Oliver, B. [Pending Publication]. A qualitative study of learner experience, acceptability, feasibility, and impact of a simulation-based educational program to build frontline capability for Shared Decision Making (SDM) in a major academic oncology center caring for people with Non-Small Cell Lung Cancer (NSCLC). *Journal of Thoracic Oncology*.
- Davies, M.** & Duffield, E. (2020). Nursing and the stage III NSCLC patient journey: a focus on durvalumab immunotherapy. *Clinical Journal of Oncology Nursing*. 24 (3): 277-284.
- National Comprehensive Cancer Network (NCCN). Thompson, J.A., Schneider, B.J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L.E., Costa, L., **Davies, M.**.....Engh, A. (2020). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Management of Immunotherapy-Related Toxicities, Version 1.2020: Featured updates to the NCCN Guidelines. *JNCCN*. 18 (3): 230-241.
- Davies, M.** & Chiang, A. (2020). Management of pneumonitis and neuropathy in patients receiving PD-1 based therapy for non-small cell lung cancer. *Journal of Oncology Practice (JOP)*. 16(2\_suppl):4s-9s. doi: 10.1200/JOP.19.00676
- Hoffner, B., Leighi, N., & **Davies, M.** (2020). Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer. *Cancer Treatment Reviews*.85 (2020) 101979.Doi:10.1016/j.ctrv.2020.101979.
- Li, J., **Davies, M.**, Ye, M., Li, Y., Huang, L., & Li, L. (2019). Impact of an animation education program on promoting compliance with active respiratory rehabilitation in postsurgical lung cancer patients. *Cancer Nursing*. (2019 Nov 8. Epub ahead of print.). doi: 10.1097/NCC.0000000000000758.
- Von Ah, D., Brown, C.G., Brown, S.J., Bryant, A.L., **Davies, M.**, Dodd, M., Ferrell, B., Hammer, M., Knobf, M.T., Knoop, T.J., LoBiondo-Wood, G., Mayer, D.K, Miaskowski, C., Mitchell, S.A., Song, L., Bruner, D.W., Wesmiller, S. & Cooley, M.E. (2019). Research Agenda for the Oncology Nursing Society: 2019-2020. *Oncology Nursing Forum*. 46 (6): 654-669.
- Davies, M.** (2019). Acute and long-term adverse events associated with checkpoint blockade. *Seminars in Oncology Nursing*. 35 (5):150926
- Davies, M.**, & Crowley, K. (2019). Narratives on Collaboration: Optimizing management of immune-related adverse events. *Journal of the Advanced Practitioner in Oncology*. June. Advance Online Publication. <https://doi.org/10.6004/jadpro.2019.10.5.9>.
- Gubens, M. A. & **Davies, M.** (2019). NCCN guidelines updates: new immunotherapy strategies for improving outcomes in non-small cell lung cancer. *JNCCN*. 17 (5.5): 574-578. May, 2019.
- M. Davies, DNP 7.2.2020

## Curriculum Vitae

- Tan, J., Chen, S., Ercolano, E., Lazenby, M., **Davies, M.** Chen, J. & McCorkle, R. (2019). The prevalence and related factors associated with psychosocial distress among 420 hospitalised lung cancer patients in China: a case study. *European Journal of Cancer Care*. April 24: e13046. Doi: 10.1111/ecc.13046.
- Davies, M.** & Eaby-Sandy, B. (2019). Management of side effects for patients receiving multimodality therapy in thoracic oncology. *J Adv Pract Oncol*. 10 (3): 245-251.
- Davies, M.** (2019). PD-1/PD-L1 inhibitors for non-small cell lung cancer: incorporating care step pathways for effective side-effect management. *J Adv Pract Oncol*. 10 (suppl 1): 21-35.
- National Comprehensive Cancer Network (NCCN). Thompson, J.A., Schneider, B.J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L.E., Costa, L., **Davies, M.**.....Wang, Y. (2019). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines<sup>®</sup>): Management of Immunotherapy-Related Toxicities (Immune Checkpoint Inhibitor-related Toxicities). Version 1.2019. JNCCN. 17 (3): 255-289.
- Brahmer, J.R., Govindan, R., Anders, R.A., Antonia, S.J., Sagorsky, S., **Davies, M.**,....Herbst, R.S. (2018). The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). *Journal for ImmunoTherapy of Cancer (JITC)*. 6:75. <https://doi.org/10.1186/s40425-018-0382-1>.
- National Comprehensive Cancer Network (NCCN). Thompson, J.A., Schneider, B.J., Brahmer, J., Andrews, S., Armand, P., **Davies, M.**..... (2018). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines<sup>®</sup>): Management of Immunotherapy-Related Toxicities (Immune Checkpoint Inhibitor-related Toxicities). Version 1.2018-February 14, 2018.
- Puzanov, I., Diab, A., Abdallah, K., Bingham III, CT., Brogden, C., Dadu, R....Ernstoff, MS. On behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group [Contributing Author]. (2017). Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. *Journal for Immunotherapy of Cancer (JITC)* 5:95.
- Davies, M.** & Duffield, E. (2017). Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events. *ImmunoTargets and Therapy*. 6:51-71.
- Davies, M.** & Shih, H. (2017). Diagnosis of Lung Cancer. *Journal of the Advanced Practitioner in Oncology*. 8 (suppl. 1): 11-23.
- Davies, M.** (2017). Fundamentals of Lung Cancer Staging. *Journal of the Advanced Practitioner in Oncology*, 8(suppl. 1): 25-34.
- Sznol, M., Postow, M.A., **Davies, M.**, Pavlick, A.C., Plimack, E.R., Shaheen, M., Veloski, C. & Robert, C. (2017). Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. *Cancer Treatment Reviews*.58: 70-76.
- Davies, M.** (2016). How checkpoint inhibitors are changing the treatment paradigm in solid tumors: what advanced practitioners in oncology need to know. *J Adv Pract Oncol*; 7:498–509.
- McCorkle, R., Jeon, S., Ercolano, E., Lazenby, M., Reid, A., **Davies, M.**, Viveiros, D. & Gettinger, S.

## Curriculum Vitae

- (2015). An advanced practice nurse coordinated multidisciplinary intervention for patients with late-stage cancer: a cluster randomized trial. *Journal of Palliative Medicine*. 18 (11): 962-969.  
DOI: 10.1089/jpm.2015.0113
- Davies, M.** (2014). New modalities of cancer treatment for NSCLC: focus on immunotherapy. *Cancer Management and Research*. 6, 1-12.
- McCorkle, R., Lazenby, M., Englehart, C., **Davies, M.**, Sipples, R., Ercolano, E. & Lyons, C. (2012). Perceptions of roles, practice patterns, and professional growth opportunities broadening the scope of advanced practice in oncology. *CJON*, 16 (4), 382-387.
- McCorkle, R., Engelking, C., Knobf, MT., Lazenby, M., **Davies, M.**, Sipples, R., Ercolano, E. & Lyons, C., (2012). Transition to a New Cancer Care Delivery System: Opportunity for Empowerment of the Role of the Advanced Practice Provider. *J Adv Pract Oncol*, 3 (1), 34-42.
- Ghetie, C., **Davies, M.**, Cornfeld, D., Suh, N. & Saif, W. (2008). Expectoration of a Lung Metastasis in a Patient with Colorectal Carcinoma. *Clinical Colorectal Cancer*, 7 (4), 283-286.
- Elligers, K., **Davies, M.**, Sanchis, D., Ferencz, T. and Saif, W. (2008). Rechallenge with Cisplatin in a Patient with Pancreatic Cancer Who Developed a Hypersensitivity Reaction to Oxaliplatin. Is Skin Test Useful in this Setting? *Journal of the Pancreas*, 9 (2), 197-202.
- Murren JR, Andersen N, Psyrrri D, Brandt D, Nadkarni R, Rose M, **Davies MJ**, Parisot N, Rosenfield AT, Pizzorno G, Zelterman D. (2005) Evaluation of irinotecan plus paclitaxel in patients with advanced non-small cell lung cancer. *Cancer Biology & Therapy*. 4:1311-5.
- Cooley, ME., McCorkle, R., Knafel, GJ., Rimer, J., Barbieri, MJ., **Davies, M.**, & Murren, JR., (2005). Comparison of Health-related Quality of Life Questionnaires in Ambulatory Oncology. *Quality of Life Research*, 14 (5) 1239-49.
- Lekakis, L., **Davies, M.**, & Murren, JR., (2004). Peer Viewpoint re: Prevention and Management of Cardiotoxicity from Antineoplastic Therapy, by Chanan-Khan, A., Srinivasan, S., & Czuczman, MS., *Supportive Oncology*, 2:3, 259.
- Hobdy, EM., Kraut, E., Masters, G., Blum, K., McKeon, A., Byrd, B., **Davies, M.**, Beaulieu, N., & Murren, J., (2004). A phase II study of topotecan and cyclophosphamide with G-CSF in patients with advanced small cell lung cancer. *Cancer Biology and Therapy*, 3:1, 89-93.
- Bleickardt, E., Argiris, A., Rich, R., Blum, K., McKeon, A., Tara, H., Zelterman, D., Burtness, B., **Davies, M.**, & Murren, JR., (2002). Phase 1 Dose Escalation Trial of Weekly Docetaxel Plus Irinotecan in Patients with Advanced Cancer. *Cancer Biology & Therapy*, 1:6, 646-650.
- Murren, JR., & **Davies, M.**, (2001). Irinotecan and Taxane Combinations for Non-Small Cell Lung Cancer. *Clinical Lung Cancer*, 2 (2), S20-S25.
- Gallipoli, M.**, & Murren, JR., (2000). CPT-11 and Paclitaxel: The Role of Non-Platinum Therapy in Non-Small Cell Lung Cancer. *Advances in Lung Cancer*, 2 (4), 5-7.
- Murren, JR., Blum, K., **Gallipoli, M.**, McKeon, A., & Rich, R., (2001). Rationale and Dose-Finding Studies of the Combination of Irinotecan and Taxane on a weekly Schedule. *Oncology*, 15 (1), (Suppl. 1).

**Non-Peer Reviewed Publications:**

- Davies, M.** (2019). ITONF Works to Close Gaps in Care Around the World. IASLC 2019 World Conference on Lung Cancer Daily News. Barcelona, Spain. September 7, 2019.
- Davies, M.** (2019). Development and Utilization of Clinical Practice Guidelines in the Management of Immune-Mediated Adverse Events. ASCO Daily News. July 17, 2019.  
<https://dailynews.ascopubs.org/doi/10.1200/ADN.19.190362/full/>.
- Davies, M.** (2019). The IASLC and the International Thoracic Oncology Nursing Forum: Celebrating Collaboration. IASLC Lung Cancer News. V4, N3. June 2019: page 6.
- Davies, M.** (2019). Nurses are crucial to developing tools, best practices for novel therapies. *ONS Voice*. 34 (6): 13. (June, 2019).
- Davies, M.** (2019). How I manage immune-related adverse events in my practice. Clinical Care Options® Oncology. Published online March 19, 2019.  
[tps://www.clinicaloptions.com/oncology/programs/irae-management/clinicalthought/ct2/page-1](https://www.clinicaloptions.com/oncology/programs/irae-management/clinicalthought/ct2/page-1)
- Davies, M. & Hennick, B.** (2018). IASLC WCLC 2018 Meeting Highlights. SITC Connect. Published online October 15, 2018. <https://www.sitcancer.org/aboutsitc/media-room/meeting-highlights/2018/iaslc-wclc>
- Herbst, R.S., **Davies, M.**, & Kenney, J.T. (2015). Updates from ASCO 2014 and ESMO 2014. *Faculty Perspectives: Latest Treatment Advances for Individualized Care of NSCLC*. 6, (1).  
<http://www.lynxcme.com/cme/oncology/48-faculty-perspectives-latest-treatment-advances-for-individualized-care-of-nsclc>
- Davies, M.**, Tucker, K., Dest, V., Lyons, C., Fitzsimons, S., & McCorkle, R., (2014). Enhancing peer review to support APN practice. *Oncology Nursing News*. 8 (8), 45.
- Davies, M.**, Fradkin, M., & Blasiak, E., (2013). Journal club bridges research and practice, improving patient care. *Oncology Nursing News*, 7 (2), 32.
- Davies, M.**, (2007). Management of novel therapeutics' side effects: a nurse-centric model. *ONS Connect*, 22 (8 Suppl.), 25-26.
- Davies, M.**, (2007). De-Mystifying genes: identifying and managing hereditary cancer. *ONS Connect*, 22 (8 Suppl.), 43-44.
- Davies, M.**, (2006). Advancing access to myeloma treatment: administration, side effects, and implications for survival. *ONS News*, 21 (8 Suppl.), 11-12.
- Davies, M.**, (2006). Strategies for Success: optimizing oral therapies in breast and colorectal cancer. *ONS News*, 21 (8 Suppl.), 7-8.

**Chapters & Books:**

## Curriculum Vitae

- Davies, M.** (2020). Psychological Issues Related to Site of Cancer: Lung Cancer. In Breibart, W.S., Butow, P.N., Jacobsen, P.B., Lam, W., Lazenby, M. & Loscalzo, M.J. (Eds.) *Psycho-Oncology* 4<sup>th</sup> Edition. New York, NY. Oxford University Press. (Pending publication)
- Davies, M.,** (2020). Endocrine Symptoms Associated with Cancer Therapies-Chapter 35 (pp335-338). In J. M. Brandt, D.G. Cope & M.G. Saria (Eds). *Oncology Nursing Society: Core Curriculum for Oncology Nursing (6<sup>th</sup> Edition)*. St Louis, MI. Elsevier. ISBN 978-0-323-59545-2
- Davies, M.,** (2019). Systemic Therapy for Non-Small Cell Lung Cancer (Chemotherapy, Targeted Therapy and Immunotherapy). In C. Langhorne & L. Sandt (Eds). *Lung Cancer Choices*, (4th Edition). Oregon City OR. Caring Ambassadors Program, Inc. ISBN 978-0-9740228-5-7
- Davies, M. & Eaby-Sandy, B.** (2019). Targeted Therapies in Lung Cancer: Management Strategies for Nurses and practitioners. M. Davies & B. Eaby-Sandy, Eds. Springer Nature Switzerland AG. ISBN 978-3-030-16549-9. ISBN 978-3-030-16550-5 (e-book)
- Andrews, S.C. & **Davies, M.** (2019). The impact and toxicity of checkpoint inhibitors in management of lung cancer (pp65-84). In. M. Davies & B. Eaby-Sandy (Eds). Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners. Switzerland, AG. Springer Nature. ISBN 978-3-030-16549-9. ISBN 978-3-030-16550-5 (e-book)
- Goodwin, K.E. & **Davies, M.** (2019). Nursing considerations for patients treated with targeted therapies. (pp105-120). In. M. Davies & B. Eaby-Sandy (Eds). Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners. Switzerland, AG. Springer Nature. ISBN 978-3-030-16549-9. ISBN 978-3-030-16550-5 (e-book)
- Davies, M.,** (2016). Systemic Therapy for Non-Small Cell Lung Cancer (Chemotherapy, Targeted Therapy and Immunotherapy). *Lung Cancer Choices*, (3<sup>rd</sup> Edition). Oregon City OR. Caring Ambassadors Program, Inc.
- Davies, M.,** (2016). Cardiac and Pulmonary Toxicities (Chapter 12, pp 491-523). In B. Gobel, S. Triest-Robertson & W. Vogel (Eds.). *Advanced Oncology Nursing Certification Review & Resource Manual 2<sup>nd</sup> Ed.* Pittsburgh, PA.: Oncology Nursing Society Press.
- Davies, M.,** (2015). Hepatotoxicity in the Cancer Patient. *inPractice<sup>®</sup> Oncology Nursing*. 2015. Available at: <http://www.inpractice.com>.
- Davies, M.,** (2015). Nephrotoxicity in the Cancer Patient. *inPractice<sup>®</sup> Oncology Nursing*. 2015. Available at: <http://www.inpractice.com>.
- Davies, M., & Reid, A.,** (2014). Chemotherapy Treatment of Non-Small Cell Lung Cancer. *Lung Cancer Choices*, (2nd Edition). Oregon City, OR. Caring Ambassadors Program, Inc.
- Davies, M.,** (2014). Pleural Effusion. In D. Camp-Sorrell & R.A. Hawkins (Eds.), *Clinical Manual for the Oncology Advanced Practice Nurse* (3rd ed., pp. 235–243). Pittsburgh, PA: Oncology Nursing Society.
- Davies, M.,** (2014). Pulmonary Embolism. In D. Camp-Sorrell & R.A. Hawkins (Eds.), *Clinical Manual for the Oncology Advanced Practice Nurse* (3rd ed., pp. 273–280). Pittsburgh, PA: Oncology Nursing Society.

## Curriculum Vitae

- Davies, M.,** (2014). Acute Renal Failure. In D. Camp-Sorrell & R.A. Hawkins (Eds.), *Clinical Manual for the Oncology Advanced Practice Nurse* (3rd ed., pp. 767–778). Pittsburgh, PA: Oncology Nursing Society.
- Davies, M.,** (2013). Hepatotoxicity in the Cancer Patient. *inPractice® Cancer*.2013. Available at: <http://www.inpractice.com>.
- Davies, M.,** (2013). Nephrotoxicity in the Cancer Patient. *inPractice® Cancer*.2013. Available at: <http://www.inpractice.com>.
- Davies, M., & Reid, A.,** (2012). Chemotherapy treatment of Non-Small Cell Lung Cancer. *Lung Cancer Choices*, (1st Edition pp 27-44). Oregon City, OR. Caring Ambassadors Program, Inc.
- Davies, M.,** (2006). Adrenal Metastasis. In D. Camp-Sorrell & R.A. Hawkins (Eds.), *Clinical Manual for the Oncology Advanced Practice Nurse* (2<sup>nd</sup> ed, pp. 647-652). Pittsburgh, PA.: Oncology Nursing Society Press.
- Davies, M.,** (2006). Acute Renal Failure. In D. Camp-Sorrell & R.A. Hawkins (Eds.), *Clinical Manual for the Oncology Advanced Practice Nurse* (2<sup>nd</sup> ed, pp. 637-645). Pittsburgh, PA.: Oncology Nursing Society Press.
- Davies, M.,** (2006). Benign Prostatic Hyperplasia. In D. Camp-Sorrell & R.A. Hawkins (Eds.), *Clinical Manual for the Oncology Advanced Practice Nurse* (2<sup>nd</sup> ed, pp. 653-659). Pittsburgh, PA.: Oncology Nursing Society Press.
- Davies, M., Houlihan, N., & Joyce, M.,** (2004). Lung Cancer Control. In N.G. Houlihan (Ed.), *Site-Specific Cancer Series: Lung Cancer*. Pittsburgh, PA.: Oncology Nursing Society Press.
- Davies, M.,** (2003). Multidisciplinary Clinic Approach to Lung Cancer. In M. Haas (Ed.), *Contemporary Issues in Lung Cancer, A Nursing Approach*. (pp 93-108). Sudbury, MA.: Bartlett Publishers.
- Davies, M., Murren, J.R., & Schultz, M.Z.,** (2002). Cardiopulmonary Toxicity of Cancer Therapy. In A.M. Berger, R.D. Portenoy, & D.E. Weissman (Eds), *Principles and Practice of Supportive Oncology* (2<sup>nd</sup> ed.), New York: Lippincott-Raven Publishers.

### Abstracts:

- Ready, N.E, Parikh, A.R, Lazure, P, Peniuta, M, **Davies, M,** Augustyniak, M, Caterino, J., Lewandowski, R., Lazar, A.J., & Murray, S. “Practice Gaps and Challenges Integrating New Immuno-Oncology Agents in the Treatment of Cancer Patients in the US: A Mixed-Method Study”. Video poster presentation during ASCO20 Virtual Scientific Program. May 29, 2020 to May 31, 2020. Virtual Annual Meeting due to COVID19.
- Herbst, R., Peterson, P, Ingram, M.F., Oliver, B., Agrawal, T., **Davies, M.,** Adelson, K. & Rudell, E. “NSCLC: Integrating the ‘Yale Model of Shared Decision-Making Solution’ into the Practice Setting”. Video poster presentation #7054 during ASCO20 Virtual Scientific Program. May 29, 2020 to May 31, 2020. Virtual Annual Meeting due to COVID19.
- Davies, M.,** Duffield, E., Medow, K. & Dest, V. “Thoracic Medical Oncology Competency Based Orientation (CBO) For the Oncology Advanced Practice Provider (APP).” Video poster presentation

## Curriculum Vitae

during the Power, Passion Purpose. **Oncology Nursing Society (ONS) 45<sup>th</sup> Annual Congress**. April 29-May 03, 2020. Presented on **ONS Bridge Virtual Congress** due to COVID19 Webinar Sept 8-17, 2020.

**Davies, M.** “The Prevalence and Related Factors Associated with Psychosocial Distress in Lung Cancer Patients in China” during *What’s New in Global Nursing – Sharing Good Practices*. International Thoracic Oncology Nursing Forum Workshop *Bridging the Gaps in Thoracic Oncology Nursing: A Global Perspective*. Held in conjunction with the International Association for the Study of Lung Cancer (IASLC) World Lung Cancer Conference. Barcelona, Spain. September 7, 2019.

Wood, L.S., Hoffner, B., Rubin, K.M., **Davies, M.**, Tushla, L.A., Guild, V. & Guild, S. (2019). Managing immune-related adverse events (IrAEs): a new educational resource for health care professionals (HCPs) and patients. Encore Poster. during *What’s New in Global Nursing – Sharing Good Practices*. International Thoracic Oncology Nursing Forum Workshop *Bridging the Gaps in Thoracic Oncology Nursing: A Global Perspective*. Held in conjunction with the International Association for the Study of Lung Cancer (IASLC) World Lung Cancer Conference. Barcelona, Spain. September 7, 2019.

Dest, V., Barbarotta, L., **Davies, M.** & McCorkle, R. (2019). Disease specific competency-based orientation (CBO) for the Oncology Nurse Practice Provider (APP). 11<sup>th</sup> Annual Janet Parkosewich Nursing Research and Evidence-Based Practice Conference. Yale New Haven Health. Yale New Haven Hospital. West Haven, CT. March 27, 2019.

Wood, L.S., Hoffner, B., Rubin, K.M., **Davies, M.**, Tushla, L.A., Guild, V. & Guild, S. (2019). Managing immune-related adverse events (IrAEs): a new educational resource for health care professionals (HCPs) and patients. Encore Poster. 2019 Oncology Nursing Conference: The Ever-Changing Landscape of Oncology Nursing: On the Edge of New Frontiers. Cleveland Clinic Taussig Cancer Institute. March 28-29, 2019.

Wood, L.S., Hoffner, B., Rubin, K.M., **Davies, M.**, Tushla, L.A., Guild, V. & Guild, S. (2019). Managing immune-related adverse events (IrAEs): a new educational resource for health care professionals (HCPs) and patients. Abstract 75 (245091). ASCO-SITC Clinical Immuno-Oncology Symposium. San Francisco, CA. February 28, 2019.

Tan, H., Chen, S., Ercolano, E., Lazenby, M., **Davies, M.**, Hoffman, E., Shen, J. & McCorkle, R. (2018). A Multi-Level Action Plan to Address Psychosocial Distress in Lung Cancer Patients in China. “Making a Difference Through Scholarship”. Yale University School of Nursing Scholar’s Day. October 26, 2018.

**Davies, M.** (2018). Development of Consensus Guidelines for the Management of Immune Mediated Toxicities. 2018 ITONF Workshop: Excellence in Oncology Care. International Thoracic Oncology Nursing Forum 2018 ITONF Workshop. Oral Session.

**Davies, M.** (2017). Evaluation in Practice from Viewpoints of Physicians and Nurses: Dimensions of Quality of Life in Lung Cancer. *Journal of Thoracic Oncology*. Oral Session: MS 14 QOL.

**Davies, M.** (2017). Immuno-oncology Overview. *Journal of Thoracic Oncology*. WS 03.15.

**Davies, M.**, (2016). Nursing and allied healthcare practitioner driven initiative to develop and integrated educational and assessment program for Immunotherapy. *Journal of Thoracic*

## Curriculum Vitae

*Oncology*. Oral OA14.02.

**Davies, M.**, (2016). Managing Toxicities of Immunotherapy in Lung Cancer Patients. *Journal of Thoracic Oncology*. Oral NU04.01

**Davies, M.**, Wood, L.S., Rubin, K., Madden, K., Brennan, L., Dahl, N., Walker, D., Li, X., & Kottschade, L., (2016). Management of endocrinopathies associated with nivolumab and ipilimumab combination therapy in advanced melanoma and other solid tumors. *JADPRO Live at APSHO 2016*. November 4, 2016. National Harbor, MD.

Kottschade, L., **Davies, M.**, Rubin, K., Madden, K., Dahl, N., Brennan, L., Walker, D., Li, X. & Wood, L. (2016). Management of gastrointestinal adverse events associated with nivolumab and ipilimumab combination therapy in advanced melanoma and other solid tumors. *JADPRO Live at APSHO 2016*. November 4, 2016. National Harbor, MD.

**Davies, M.**, Wood, L.S., Rubin, K., Madden, K., Brennan, L., Dahl, N., Walker, D., Li, X. & Kottschade, L. (2016). Management of endocrinopathies associated with nivolumab and ipilimumab combination therapy in advanced melanoma and other solid tumors. [Encore Presentation]. *Fifteenth International Kidney Cancer Symposium*. November 4-5, 2016. Miami, FL.

Kottschade, L., **Davies, M.**, Rubin, K., Madden, K., Dahl, N., Brennan, L., Walker, D., Li, X., & Wood, L., (2016). Management of gastrointestinal adverse events associated with nivolumab and ipilimumab combination therapy in advanced melanoma and other solid tumors. [Encore Presentation]. *Fifteenth International Kidney Cancer Symposium*. November 4-5, 2016. Miami, FL.

**Davies, M.**, Altan, M., Chiang, A., Crowley, K., Dest, V., Duffield, E., Gerrish, H., Gettinger, S., Goldberg, S., Lilenbaum, R., Rowen, E. & Herbst, R. (2016). Identification and management of cardio-pulmonary toxicities of targeted therapies –a multidisciplinary approach. *16<sup>th</sup> Annual Targeted Treatment of Lung Cancer Meeting. International Association for the Study of Lung Cancer (IASLC)*. February 17-20, 2016. Santa Monica, CA.

Duffield, E., Altan, M., Chiang, A., **Davies, M.**, Dest, V., Gerrish, H., Gettinger, S., Goldberg, S., Lilenbaum, R., Rowen, E., & Herbst, R., (2016). Dermatologic complications of immune therapy: lessons learned from four case studies. *16<sup>th</sup> Annual Targeted Treatment of Lung Cancer Meeting. International Association for the Study of Lung Cancer (IASLC)*. February 17-20, 2016. Santa Monica, CA.

Lingard, K., **Davies, M.**, & Hodgetts, J., (2015). Optimizing the Delivery of Patient Care with the Immune Checkpoint Inhibitor Nivolumab in Patients with Advanced Melanoma (MEL). *UKONS Annual Conference 2015*. November 13-14, 2015. Birmingham, United Kingdom.

**Davies, M.**, & Tucker, K., (2015). Development and Implementation of a Peer Review Process for APRNs. *JADPRO Live at APSHO 2015*. November 6, 2015. Phoenix, AZ.

**Davies, M.**, (2015). Enhancing Physical Wellbeing in Lung Cancer. *Journal of Thoracic Oncology*. 10 (9), Suppl. 2 Oral 43.04.

**Davies, M.**, Duffield, E., & Rowen, E., (2015). Identification & Management of Unique Immune Mediated Toxicities. *Journal of Thoracic Oncology*. 10 (9), Suppl. 2. Oral 15.02.

## Curriculum Vitae

- Davies, M.,** Tucker, K., & Fitzsimons, S., (2015). Development of the Peer Review Process for Advanced Practice Registered Nurses. *Joseph A. Zaccagnino Patient Safety and Clinical Quality Conference. Yale New Haven Health System.* May 19, 2015. Bridgeport, CT.
- Davies, M.,** Dest, V., Gerrish, H., Rowen, E., & Duffield, E., (2015). Identification and management of immune mediated toxicities associated with immune checkpoint inhibitors: utilizing a focused algorithm. *7<sup>th</sup> Annual Nursing Research and Evidence-Based Practice Conference. Yale-New Haven Hospital.* April 2. New Haven, CT.
- Davies, M.,** & Tucker, K., (2015). Development of the peer review process for advanced practice registered nurses. *7<sup>th</sup> Annual Nursing Research and Evidence-Based Practice Conference. Yale-New Haven Hospital.* April 2. New Haven, CT.
- Davies, M.,** Chiang, A., Dest, V., Duffield, E., Gerrish, H., Gettinger, S., Goldberg, S., Lilenbaum, R., Rowen, E., & Herbst, R., (2015). Diagnosis and management of toxicities caused by immune checkpoint blockade. *15<sup>th</sup> Annual Targeted Treatment of Lung Cancer Meeting. International Association for the Study of Lung Cancer (IASLC).* Santa Monica, CA.
- Davies, M.,** Dest, V., Lyons, C., & McCorkle, R., (2014). Transforming peer review for advanced practice nurses. *Oncology Nursing Forum*, 41, (2), E64-E171 (abstract #84).  
Doi:10.1188/14.ONF.E64-E171.
- Davies, M.,** (2014). Immune checkpoint inhibitors managing unique immune related endocrine side effects. *14<sup>th</sup> Annual Targeted Treatment of Lung Cancer Meeting. International Association for the Study of Lung Cancer (IASLC).* Santa Monica, CA.
- Davies, M.,** & McDonnell, T., (2012). Assessment of oncology advanced practice providers criteria for inclusion in a clinical ladder program to promote professional development in two academic medical centers. *Oncology Nursing Forum*. 39, (6), abstract #1421806.
- Davies, M.,** Fradkin, M., & Blasiak, E., (2012). An advanced practice nurse-led oncology journal club to promote research dissemination. *Sixteenth Annual Nursing Research & Evidenced-Based Practice Conference.* The Connecticut Nursing Research Alliance Evidenced-Based Practice: Outcome-Focused Innovations.
- Davies, M.,** Fradkin, M., & Blasiak, E., (2012). "Smilow Society"- an oncology nursing journal club to promote research dissemination. *Oncology Nursing Forum*. 39, (3). Abstract #1319350
- Baumgart, M., Acevedo-Gadea, C., Wang, Z., Butta, E., **Davies, M.,** Deshpande, H., Decker, R., Sasaki, C., Judson, B., Son, Y., Herbst, RS., & Morgensztern, D., (2012). Prognostic impact of Extracapsular Extension in squamous cell carcinoma of the head and neck. *Journal of Clinical Oncology*. 30 (15S), abstract #5532.
- Acevedo-Gadea, C., Baumgart, M., Wang, Z., Deshpande, H., **Davies, M.,** Judson, B., Decker, R., Sasaki, C., Herbst, RS. & Morgensztern D., (2012). Prognostic impact of the AJCC staging in patients with squamous cell carcinoma of the oropharynx. *Journal of Clinical Oncology*. 30 (15S), abstract #5529.
- Sha, M.M., Hotchkiss, S., Shanley, J., **Davies, M.,** Ferencz, T., Syrigos, K. and Saif, W., (2008). Successful desensitization with cetuximab (CET) after hypersensitivity reaction (HSR) to panitumumab (PAN) and CET in patients with metastatic colorectal cancer. *Journal of Clinical*

## Curriculum Vitae

*Oncology*. 26, (15S), abstract #15092.

Potter, V., **Davies, M.**, Peccerillo, J., and Saif, W., (2008). Successful re-challenge with panitumumab in patients with GI cancers who develop hypersensitivity reactions to cetuximab. *Journal of Clinical Oncology*. 26, (15S), abstract #20744.

**Davies, M.** (2004). Development and Implementation of Nurse Practitioner Mentorship Program. *Oncology Nursing Forum*. 31 (6).

### **Other Publications:**

#### **Presentations (Past 10 years):**

**Davies, M.** (October 24, 2020). Maximizing the Benefits and Minimizing the Risks of Cancer Immunotherapies in Everyday Oncology Practice: Need-to-Know Information and Practical Guidance for Oncology Nurses. PeerView Institute for Medical Education, CME. Oncology Nursing Society, Boston, MA. Virtual Presentation.

**Davies, M.** (October 13, 2020). Maximizing the Benefits and Minimizing the Risks of Cancer Immunotherapies in Everyday Oncology Practice: Need-to-Know Information and Practical Guidance for Oncology Nurses. PeerView Institute for Medical Education, CME. Oncology Nursing Society, Richmond, Virginia. Virtual Presentation.

**Davies, M.** (September 26, 2020). Advances in Treatment of Non-Small Cell Lung Cancer: the Latest in Immunotherapy. Virtual Advanced Practice Providers Oncology Summit. Horizon CME. Philadelphia, PA.

Miaskowski, C., **Davies, M.**, Wesmiller, S.W. & Hammer, M.J. on behalf of the ONS Research Committee. (September 8, 2020). "What's Next? Advancing Oncology Symptom Science Research". Oncology Nursing Society Congress. ONS Bridge Virtual Meeting. (Taped July 22, 2020; Live On-Line September 8, 2020)

**Davies, M.** (August 1, 2020). "Multidisciplinary Management of Immunotherapy-Related Adverse Events." 4<sup>th</sup> Annual School of Oncology Nursing. Physician Education Resource (PER) CME, MJH Live Interactive Webcast.

**Davies, M.** & Sharon, E. (November 9, 2019). "Concurrent Session 308: Clinical Management". Session Moderators. Society for Immunotherapy of Cancer (SITC) 34<sup>th</sup> Annual Meeting. National Harbor, Maryland.

**Davies, M.** (November 10, 2019). "Food and Drug Administration Update". Session Moderator. Society for Immunotherapy of Cancer (SITC) 34<sup>th</sup> Annual Meeting. National Harbor, Maryland.

**Davies, M.** (November 2, 2019). "Updates on Immune Checkpoint Therapy and the Management of Associated Toxicities". Oncology Nurses Connecting in Connecticut. All Chapter Symposium: SWCONS-CCONS. 2019 Annual Oncology Nursing Symposium. Rocky Hill, Connecticut.

## Curriculum Vitae

- Davies, M. & Bourenane, S.** (September 30, 2019). “Identification, Triage, and Management of Immune-Related Adverse Effects in Patients with Cancer Presenting to the Emergency Department: Practical Guidance for Emergency Nurses”. PeerView Institute for Medical Education. Emergency Nursing 2019. Emergency Nurses Association. Annual Conference. Austin, Texas.
- Davies, M.** (September 21, 2019). “Updates on the Utilization of Immune Checkpoint Therapy: Considerations for the Management of Toxicities”. Southeastern Connecticut Oncology Nursing Conference. Smilow Cancer Care Center at Waterford. Smilow Cancer Hospital @ Yale. New London, Connecticut.
- Davies, M.** (September 14, 2019). “The Role of Immune Checkpoint Inhibitors with and without combination therapy for nonmutated metastatic NSCLC”. The JADPRO Lung Cancer Conference: “From Inquiry to Investigation to Insight: Clinical Clarity in Non-Small Cell Lung Cancer”. New York, New York.
- Davies, M.** (September 14, 2019). “Managing Immune-Related Adverse Events”. The JADPRO Lung Cancer Conference: “From Inquiry to Investigation to Insight: Clinical Clarity in Non-Small Cell Lung Cancer”. New York, New York.
- Davies, M.** (September 7, 2019). “The Prevalence and Related Factors Associated with Psychosocial Distress in Lung Cancer Patients in China” during *What’s New in Global Nursing – Sharing Good Practices*. International Thoracic Oncology Nursing Forum Workshop *Bridging the Gaps in Thoracic Oncology Nursing: A Global Perspective*. Held in conjunction with the International Association for the Study of Lung Cancer (IASLC) World Lung Cancer Conference. Barcelona, Spain.
- Davies, M, Eaby-Sandy B & Thomas R.** (September 7, 2019). Management of Immune Related Adverse Events in Lung Cancer: A Case Based Approach. International Thoracic Oncology Nursing Forum Workshop *Bridging the Gaps in Thoracic Oncology Nursing: A Global Perspective*. Held in conjunction with the International Association for the Study of Lung Cancer (IASLC) World Lung Cancer Conference. Barcelona, Spain.
- Davies, M** (August 17, 2019). Tumor Genetics: Informing Treatment Decisions in Non-Small Cell Lung Cancer (NSCLC). Advanced Practice Providers Oncology Summit. Horizon CME. New York, NY.
- Davies, M.** (August 3, 2019). Multidisciplinary Management of Immune Mediated Adverse Events. 3<sup>rd</sup> Annual School of Nursing-Oncology. Physician Education Resource (PER) CME, MJH Live Events. San Diego, CA.
- Davies, M.** (April 26, 2019). Best Practices in Immunotherapy Symptom Management and Patient Education. SWOG Immune-Related Adverse Events Symposium. San Francisco, CA.
- Davies, M.** (March 23, 2019). NCCN Guidelines Updates: New Immunotherapy Strategies for Improving Outcomes in Non-Small Cell Lung Cancer. NCCN 2019 Annual Conference. Improving the Quality, Effectiveness and Efficiency of Cancer Care. Orlando, Florida.

## Curriculum Vitae

- Davies, M.** (March 22, 2019). Best Practices in Immunotherapy Symptom Management and Patient Education. 2019 NCCN Nursing Program: Advancing Oncology Nursing. NCCN 2019 Annual Conference. Improving the Quality, Effectiveness and Efficiency of Cancer Care. Orlando, Florida.
- Davies, M.** (March 1, 2019). *Tumor Board: Toxicity Management and Moderating Case Reports. Multidisciplinary Considerations.* ASCO-SITC Clinical Immuno-Oncology Symposium. San Francisco, California. <https://www.facebook.com/IOEssentials/videos/634373153670338/>
- Davies, M.** (February 28, 2019). *Multidisciplinary Management of Immune Related Adverse Effects.* 2019 ASCO-SITC Clinical Immuno-Oncology Symposium. San Francisco, California.
- Davies, M. & Eaby-Sandy, B. (November 3, 2018). *Management of Side Effects for Patients Receiving Multimodality Therapy in Thoracic Oncology.* 2018 JADPRO Live: Bringing Clarity to Complexity. Advanced Practitioner Society for Hematology & Oncology (APSHO) Annual Conference. Hollywood, Florida.
- Davies, M. (November 1, 2018).** *Endocrine Issues in the Oncology Setting: Challenges for the Treating Practitioner.* Pre-Conference Workshop: Primary Care and the Patient with Cancer. 2018 JADPRO Live: Bringing Clarity to Complexity. Advanced Practitioner Society for Hematology & Oncology (APSHO) Annual Conference. Hollywood, Florida.
- Davies, M.** (October 27, 2018). *Managing Immune Therapy irAEs in Lung Cancer and Head & Neck Cancer: Professor Discussion.* 11<sup>th</sup> Annual Symposium on Personalized Therapies & Best Clinical Practices for Lung Cancer and Head & Neck Cancers. BioMedical Learning Institute (BMLI) Oncology Learning Center. San Francisco, CA.
- Davies, M.** (October 12, 2018). *Managing Toxicities with Systemic Therapy for Lung Cancer and Head & Neck Cancer.* 2018 Lung Cancer and Head & Neck Cancer Master Class. BioMedical Learning Institute (BMLI) Oncology Learning Center. Dallas, TX.
- Davies, M., McPhelim, J., Fraser, A. & Eaby-Sandy, B.** (September 23, 2018). *Toxicity Management of Immunotherapy Treatments in Lung Cancer and Mesothelioma.* 2018 International Thoracic Oncology Nursing Forum (ITONF) Workshop: Excellence in Thoracic Oncology Care. IASLC 19<sup>th</sup> WCLC. Toronto, Canada.
- Davies, M.** (September 23, 2018). *Development of Consensus Guidelines for the Management of Immune Mediated Toxicities.* 2018 International Thoracic Oncology Nursing Forum (ITONF) Workshop: Excellence in Thoracic Oncology Care. IASLC 19<sup>th</sup> WCLC. Toronto, Canada.
- Davies, M.** (September 15, 2018). *Overview of the Immune System and Immune Checkpoint Targets and their MOAs.* Clinical Advances and Case Studies in Immune Checkpoint Inhibitors in Oncology. JADPRO<sup>®</sup> Regional Lectures. Dallas, Texas.
- Davies, M.** (September 15, 2018). *Non-Small Cell Lung Cancer.* Clinical Advances and Case Studies in Immune Checkpoint Inhibitors in Oncology. JADPRO<sup>®</sup> Regional Lectures. Dallas, Texas.
- Davies, M.** (September 15, 2018). *Head & Neck Squamous Cell Carcinoma.* Clinical Advances and Case Studies in Immune Checkpoint Inhibitors in Oncology. JADPRO<sup>®</sup> Regional Lectures. Dallas, Texas.
- Davies, M.** (August 4, 2018). *Lung Cancer: Systemic Toxicity Management, Supportive and Palliative Care.* 2<sup>nd</sup> Annual School of Nursing™. Physicians Education Resource, LLC. Chicago, IL.

## Curriculum Vitae

- Davies, M.** & Eaby-Sandy, B. (August 4, 2018). *Treatment of Non-Small Cell Lung Cancer Case Review: An Ivy League Debate*. 2<sup>nd</sup> Annual School of Nursing™. Physicians Education Resource, LLC. Chicago, IL.
- Davies, M.** (August 4, 2018). *Multidisciplinary Management of Immunotherapy-Related Adverse Events*. 2<sup>nd</sup> Annual School of Nursing™. Physicians Education Resource, LLC. Chicago, IL.
- Davies, M.** (July 14, 2018). *New and Emerging Immunotherapies: Management of Treatment Related Toxicities*. Advanced Practice Providers Oncology Summit. Horizon CME. Philadelphia, PA.
- Davies, M.**, Chiang, A., Derosier, K., Jin, B., Blatt, L. & Kapo, J. (June, 2018) “*Management of Patients with Dual Diagnosis: Challenges of Mental Illness*”. Schwartz Center Rounds, Yale Cancer Center & Smilow Cancer Center at Yale New Haven, New Haven, CT.
- Davies, M.** (April 7, 2018). *Improving the Journey: Role of Patient Reported Outcomes*. Invited Keynote Speaker. 7<sup>th</sup> Australian Lung Cancer Conference. Lung Foundation Australia. Sydney, New South Wales, Australia.
- Davies, M.** (April 7, 2018). *Impact of Lung Cancer: Lung Cancer in Women, Lung Cancer in CALD communities, Indigenous Peoples and Lung Cancer*. Invited Session Discussant. 7<sup>th</sup> Australian Lung Cancer Conference. Lung Foundation Australia. Sydney, New South Wales, Australia.
- Davies, M.** (April 6, 2018). *Stigma and Survivorship: When you care for someone with lung cancer-smoking related stigma and the impact on families*. Invited Speaker. 7<sup>th</sup> Australian Lung Cancer Conference. Lung Foundation Australia. Sydney, New South Wales, Australia.
- Davies, M.** (April 5, 2018). *Skin Toxicities in Anti-Cancer Therapy in Lung Cancer*. Invited Keynote Speaker. Australian-New Zealand Lung Cancer Nursing Forum. Workshop. 7<sup>th</sup> Australian Lung Cancer Conference. Lung Foundation Australia. Sydney, New South Wales, Australia.
- Davies, M.** (April 5, 2018). *Immunotherapy and Guidelines from the Nurses Perspective*. Invited Plenary Speaker. Australian-New Zealand Lung Cancer Nursing Forum. Workshop. 7<sup>th</sup> Australian Lung Cancer Conference. Lung Foundation Australia. Sydney, New South Wales, Australia.
- Davies, M.** & Rohan, K. (March 24, 2018). *Immunotherapy: Nursing and Allied Health Professions Perspectives*. Invited Workshop Coordinator and Speaker. IASLC Lung Cancer Immunotherapy Meeting. Madrid Spain.
- Davies, M.** (November 11, 2017). *Immune Therapy Toxicity Management: Nursing Considerations to Improve Patient Outcomes*. 2<sup>nd</sup> Annual Symposium on Integrating Immune Therapies and Targeted Therapies into Standards of Care for Hematologic and Solid Malignancies. BioMedical Learning Institute (BMLI) Oncology Learning Center. San Francisco, CA.
- Davies, M.** (November 8, 2017). *New Standards of Care and Emerging Agents in Immunotherapy*. 35<sup>th</sup> Annual Chemotherapy Foundation Symposium (CFS): Innovative Cancer Therapy for Tomorrow. Physician Education Resource, LLC. New York, NY.
- Davies, M.**, Pallin, D. & Postow, M. (October 28, 2017). *Oncologic Emergencies in the ED: Recognizing and Managing Adverse Reactions Associated with Modern Cancer Therapies, Essential Guidance*

## Curriculum Vitae

*for Emergency Medicine Specialists*. PeerView Institute for Medical Education. American College of Emergency Physicians (ACEP) Scientific Assembly. Washington, D.C.

**Davies, M.** (October 24, 2017). *Immune Therapy Toxicity Management and Nursing Clinical Issues*. 2<sup>nd</sup> Annual Immune Therapies for Cancer Master Class. BioMedical Learning Institute (BMLI) Oncology Learning Center. Dallas, TX.

**Davies, M.** (October 21, 2017). *Improving Patient Outcomes in Lung Cancer: Nursing Clinical Issues*. 10<sup>th</sup> Annual Symposium on Personalized Therapies & Best Clinical Practices for Lung Cancer and Head & Neck Cancers. BioMedical Learning Institute (BMLI) Oncology Learning Center. Los Angeles, CA.

**Davies, M.** (October 17, 2017). *Evaluation in Practice from Viewpoints of Physicians and Nurses: Dimensions of Quality of Life in Lung Cancer*. Oral Session: MS 14 QOL. 18<sup>th</sup> International Association for the Study of Lung Cancer (IASLC) World Lung Cancer Conference. Yokohama, Japan.

**Davies, M.** (October 15, 2017). *Immuno-oncology Overview*. International Thoracic Oncology Nursing Forum (ITONF) 2017 Workshop. Session: WS 03.15. 18<sup>th</sup> International Association for the Study of Lung Cancer (IASLC) World Lung Cancer Conference. Yokohama, Japan.

**Davies, M.** (September 16, 2017). *Nursing Perspective on irAEs: Patient Education, Monitoring and Management*. *Advances in Cancer Immunotherapy™*. Society for Immunotherapy of Cancer (SITC). New Haven, CT.

**Davies, M. & Kluger, H.** (September 16, 2017). *Management and Mitigation of irAEs for Immunotherapy Prescribers*. *Advances in Cancer Immunotherapy™*. Society for Immunotherapy of Cancer (SITC). New Haven, CT

**Davies, M.** (August 5, 2017). *Clinical Applications: management of toxicities associated with immunotherapy*. 1<sup>st</sup> Annual School of Nursing™. Physicians Education Resource, LLC. Nashville, TN.

**Davies, M. & Cherry, G.** (August 5, 2017). *Immunotherapy Case Discussion*. 1<sup>st</sup> Annual School of Nursing™. Physicians Education Resource, LLC. Nashville, TN.

**Davies, M.** (July 21, 2017). *Managing Toxicities of Newer Agents*. National Comprehensive Cancer Network (NCCN) Lung Cancer Congress Series. Baltimore, MD.

**Davies, M.** (July 14, 2017). *Immune Checkpoint Inhibitors in Cancer: What APPs Need to Know*. Advanced Practice Providers Oncology Summit. Horizon CME. Philadelphia, PA.

**Davies, M.** (March 17, 2017) *Overview of Immunotherapy: Patient Benefits and Criteria for Evaluating, Grading, and Treatment of Adverse Events. Expert Insights and Key Nursing Considerations: Treating and Caring for Patients with Lung Cancer*. Chicago Thoracic Oncology Nursing Summit. Rush University Medical Center & PleXus Communications.

**Davies, M.** (March 11, 2017) *Upfront Treatment of Non-Small Cell Lung Cancer in Patients Lacking an Identifiable Activating Mutation*. PCE Oncology Conference Series. Practicing Clinicians Exchange. Melville, NY.

## Curriculum Vitae

- Davies, M. & Sznol, M.** (February 24, 2017) *Maximizing the Therapeutic Potential of Immune Checkpoint Blockade Across the Oncologic Spectrum: Guidance for Assessment of Response and Management of Immune-Related Adverse Effects. Ancillary Symposium.* PeerView Institute for Medical Education. ASCO-SITC Clinical Immuno-Oncology Symposium. Orlando, FL.
- Davies, M.** (February 23, 2017) *Immune Checkpoint Inhibitors. Session Chair. 17<sup>th</sup> Annual Targeted Therapies of the Treatment of Lung Cancer.* International Association for the Study of Lung Cancer. Santa Monica, CA.
- Davies, M.** (February 3, 2017) *Management of Toxicities with Immunotherapy: What have we learned in 6 years? What challenges does the future present? The Lung Cancer Master Class.* BioMedical Learning Institute (BMLI) Oncology Learning Center. Dallas, TX.
- Davies, M.** (December 6, 2016) *Nursing and allied healthcare practitioner driven initiative to develop and integrated educational and assessment program for Immunotherapy.* Oral OA14.02. 17<sup>th</sup> International Association for the Study of Lung Cancer (IASLC) World Lung Cancer Conference. Vienna, Austria.
- Davies, M.** (December 6, 2016) *Managing Toxicities of Immunotherapy in Lung Cancer Patients.* Oral NU04.01 17<sup>th</sup> International Association for the Study of Lung Cancer (IASLC) World Lung Cancer Conference. Vienna, Austria.
- Davies, M.** (November, 2016) *Case Studies in Metastatic NSCLC and Metastatic HNSCC.* Cancer Center at Beth Israel Deaconess Medical Center, Duxbury, MA.
- Davies, M.** (October, 2016) *Immunotherapy in the Oncology Patient.* Multi-Specialty Advanced Practice Provider (APP) CME Conference. Yale New Haven Health System: Yale New Haven Hospital. New Haven, CT.
- Davies, M.** (October 2016) *Immuno-Oncology: A New Era in NSCLC Therapy. Best Practices in Lung Cancer Navigation.* Academy of Oncology Nurse & Patient Navigators. Chicago, IL.
- Davies, M.** (October 2016) *The Rise of the Patient in Shaping Cancer Research and Treatment.* The 2016 Strategic Cancer Business Master Class. Oncology Learning Center. Dallas, TX.
- Davies, M.** (October 2016) *The Rise of the Patient in Cancer Therapy: Value and Therapy Selection.* 9<sup>th</sup> Annual Symposium on Personalized Therapies & Best Clinical Practices for Lung Cancer. BMLI. San Francisco, CA.
- Davies, M.** (September 2016) *Management of Patients Treated with Cytotoxic Chemotherapy. Collaborative Practice in the Management of Patients with Non-Small Cell Lung Cancer.* APSHO Regional Lecture Series. Levine Cancer Institute. Charlotte, NC.
- Davies, M.** (September 2016) *The Role of the Nurse and Nurse Practitioner with Targeted and Immunotherapy for Cancer.* 1<sup>st</sup> Annual Symposium on Integrating Immune Therapies & Targeted Therapies into Standards of Care for Solid & Hematologic Malignancies. BMLI. San Francisco, CA.
- Davies, M.** (September, 2016) *Foundational Principles and Practical Application of Immunotherapies for Oncology Nurses and Pharmacists.* AXIS Medical Education. Central Massachusetts ONS. Worcester, MA.

## Curriculum Vitae

- Davies, M.** (July, 2016) *Management of Patients Treated with Immunotherapy. Collaborative Practice in the Management of Patients with Non-Small Cell Lung Cancer.* APSHO Regional Lecture Series. University of Alabama at Birmingham Hospital. Birmingham, AL.
- Davies, M.** (June, 2016) *Management of Patients Treated with Immunotherapy. Collaborative Practice in the Management of Cancer Patients with Non-Small Cell Lung Cancer.* APSHO Regional Lecture Series. NYU Langone's Perlmutter Cancer Center. New York, NY.
- Davies, M.** (June, 2016) *Overview & Management of Patients with Immunotherapy.* Lawrence & Memorial Hospital Cancer Center, Waterford, CT.
- Davies, M.,** Blatt, L., Massaro, S., Galvin, M.J., Lasalle, M. & Beales, C. (May, 2016) "Lost in Transition". Schwartz Center Rounds, Yale Cancer Center & Smilow Cancer Center at Yale New Haven, New Haven, CT.
- Davies, M.,** Herbst, R., Lipson, E., Seery, V.J. & Love, N. (April, 2016) *Cancer Immunotherapy-Oncology Grand Rounds. Research to Practice.* Oncology Nursing Society 41<sup>st</sup> Annual Congress Satellite Symposium. San Antonio, TX.
- Davies, M.** (December, 2015) *Advances in the Principles of Immunotherapy.* Smilow Cancer Hospital Nursing Grand Rounds. Smilow Cancer Hospital at Yale New Haven.
- Davies, M.,** Lingard, K. & Hodgetts, J. (November, 2015) *Optimizing the Delivery of Patient Care with the Immune Checkpoint Inhibitor Nivolumab in Patients with Advanced Melanoma (MEL).* Oral Presentation. UKONS Annual Conference 2015. Birmingham, United Kingdom.
- Davies, M.** (November, 2015) "Patient Encounters of the Difficult Kind". Schwartz Center Rounds, Yale Cancer Center & Smilow Cancer Center at Yale New Haven, New Haven, CT.
- Davies, M.** (October, 2015) *Lung Cancer Update.* The Boston Oncology Nursing Society 2015 Oncology Updates Seminar. Dorchester, MA.
- Davies, M.** (October, 2015) *Managing and Preventing Immune-Related Side Effects with Checkpoint Inhibition: What have we learned and how can we help our patients.* 8<sup>th</sup> Annual Symposium on Personalized Therapies and Best Clinical Practices for Lung Cancer. BMLI. San Francisco, CA.
- Davies, M.** (September, 2015) *Enhancing Physical Wellbeing in Lung Cancer.* Oral 43-Discussant. 16<sup>th</sup> World Conference on Lung Cancer. Denver, CO.
- Davies, M.** (September, 2015) *Identification & Management of Unique Immune Mediated Toxicities.* Oral Session 15. 16<sup>th</sup> World Conference on Lung Cancer. Denver, CO.
- Davies, M.,** Eaby-Sandy, B., Sipples, R. & Shelton, G. (April 2015) *Oncology Nursing Perspectives on the Evolving Management of NSCLC.* Oncology Nursing Society 40<sup>th</sup> Annual Congress. Educational Concepts Group (ECG) & Postgraduate Institute for Medicine (PIM). Roundtable Symposium Webcast. Orlando, FL.
- Davies, M.,** Luke, J.J. & Esper, P. (April 2015) *Understanding the Immune System and Checkpoint Inhibitors in Solid Tumors: What Oncology Nurses Need to Know.* Oncology Nursing Society 40<sup>th</sup> Annual Congress. Satellite Symposium. Orlando, FL.

## Curriculum Vitae

- Davies, M.** (April, 2015) *OPDIVO: A New Approach for Previously Treated Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)*. Oncology Nursing Society 40<sup>th</sup> Annual Congress. Satellite Symposium, Orlando, FL.
- Davies, M.** (October, 2014) *Managing Immunotherapy Side Effects. Immunotherapy for Melanoma, Kidney & Lung*. GRACE Immunotherapy Forum. Chicago, IL.
- Davies, M.** (October 2014) *Recognizing and Managing unique side effects and responses of immune therapy in lung cancer*. 7<sup>th</sup> Annual Symposium on Personalized Therapies and Best Clinical Practices for Lung Cancer. San Francisco, CA.
- Davies, M.** (October, 2014) *Development of a Journal Club Training Workbook to Enhance Competence & Confidence of Journal Club Facilitators*. The 18<sup>th</sup> Annual Evidence Based Practice Conference. The Connecticut Nursing Research Alliance. Hartford, CT.
- Davies, M.** (September-November 2014) *Launching Journal Clubs in the Clinical Setting*. Nursing Shared Governance Fall 2014 Evidence-Based Practice Workshop Series. Yale-New Haven Hospital. New Haven, CT .
- Davies, M.** (June, 2014) *Utilizing a Strategic Planning Approach to Transform Peer Review for Advanced Practice Nurses*. Yale School of Nursing. West Haven, CT.
- Davies, M.** (April, 2014) *Development of an Advanced Practice Nurse Council*. Stamford Hospital Advanced Practice Nurse Council Meeting. Stamford, CT.
- Davies, M.** (February, 2014) *Advanced Practice Nurse Council Development and Peer Review Integration*. Middlesex Hospital Advanced Practice Nurse Council Meeting. Middlesex, CT.
- Davies, M. & Tucker, K.** (February, 2014) *Supporting the integration of advanced practice nurses to enhance the patient care experience*. The Connecticut Hospital Association. Patient Care Executive Committee Meeting. Wallingford, CT.
- Davies, M.** (November, 2103) *Patient Management Issues Unique with Immunotherapy in NSCLC*. 6<sup>th</sup> Annual Symposium on Personalized Therapies and Best Clinical Practices for Lung Cancer. BioMedical Learning Institute (BMLI). Los Angeles, CA.
- Davies, M.** (November, 2013) *Integration of the Advanced Practice Nurse into Practice Settings*. The Connecticut Hospital Association. Physician Executive Committee Meeting. Wallingford, CT.
- Davies, M.** (October, 2013) *Unit Based Journal Clubs*. The 17<sup>th</sup> Annual Evidence Based Practice Conference. The Connecticut Nursing Research Alliance, Hartford, CT.
- Davies, M.** (July, 2012) *Entry into Practice: The New APN*. Panel Discussion. Columbia University School of Nursing Management in Advanced Practice Course. New York, NY.
- Davies, M.** (May, 2102) *"Smilow Society"- an oncology nursing journal club to promote research dissemination*. Yale-New Haven Hospital Nursing Research & Evidenced Based Practice Presentation. New Haven, CT.
- Davies, M.** (May 2012) *The APP Time: Pillars & Time for Change*. Oncology Nursing Grand Rounds. Smilow Cancer Hospital at Yale-New Haven. New Haven, CT.

## Curriculum Vitae

- Davies, M.** (June, 2012) *Prevention of CINV-The Nurses Perspective*. Eisai Headquarters, Woodcliff Lake, NJ.
- Davies, M.** (October, 2012) *Oncology Nurses: Providing Support System for Cancer Care*. Yale Cancer Center Answers WNPR Broadcast. New Haven, CT.
- Davies, M.,** Deshpande, H. & Desrosier, K. (September, 2010) *Disconnect Between the Family and Medical Team*. Schwartz Center Rounds, Yale Cancer Center & Smilow Cancer Center at Yale New Haven, New Haven, CT.
- Davies, M.** (March, 2009) *Prevention of Chemotherapy Induced Nausea & Vomiting. (Oral)*. St Vincent's Hospital and NYU Hospital Oncology Nursing Group. New York, NY.
- Davies, M.** (February, 2009) *Prevention of Chemotherapy Induced Nausea & Vomiting*. Greater New Haven Oncology Nursing. New Haven, CT.
- Davies, M.** (June, 2008) *Provider-Patient Communication in Oncology-Promoting Patient Adherence*. Connecticut Oncology Group. Middletown, CT.
- Davies, M.** (May, 2008) *Provider-Patient Communication in Oncology-Promoting Patient Adherence*. Columbia Presbyterian Hospital Oncology Unit. New York, NY.
- Davies, M.** (May, 2008) *Quality Care in Oncology-Raising Awareness and Increasing Participation in Clinical Trials*. Department of Nursing Grand Rounds. Hartford Hospital. Hartford, CT.
- Davies, M.** (January, 2008) *Advances in Renal Cell Carcinoma*. Brey Cancer Center. The Hospital of Central Connecticut. New Britain, CT.
- Davies, M.** (November, 2007) *Chemotherapy Induced Nausea & Vomiting (CINV)-Round Table Discussion*. Yale-New Haven Hospital Medical Oncology Nursing Staff. New Haven, CT.
- Davies, M.** (October, 2007) *Cancer Related Fatigue-Finding Balance. Challenges in Adult & Pediatric Oncology Nursing Practice*. Sixth Annual Oncology Nursing Conference. Oncology Nursing Council at Yale New Haven Hospital. New Haven, CT.
- Davies, M.** (October, 2007) *New Strategies in the Management of Chemotherapy Induced Nausea & Vomiting*. Northwest Oncology Nursing Society Chapter Meeting. Worcester, MA.
- Davies, M.** (October, 2007) *Update on Advances with Multikinase Inhibitors in Renal Cell Carcinoma*. Southwest Oncology Nursing Society Chapter Meeting. New Haven, CT.
- Davies, M.** (June, 2007) *Updates in the Treatment of Renal Cell Cancer*. Western Connecticut Oncology Nursing Society Local Chapter Meeting. Brookfield, CT.
- Davies, M.** (May, 2007) *Updates in the Treatment of Renal Cell Cancer*. Oncology Nursing Society Hartford Chapter Meeting. West Hartford, CT.
- Davies, M.** (February, 2007) *The Supporting Role of Oncology Nurses*. Yale Cancer Center Answers WNPR Broadcast. Radio Broadcast. New Haven, CT.

## Curriculum Vitae

- Davies, M.** (November, 2006) *New Advances in the Treatment of Chemotherapy Induced Nausea & Vomiting*. Southwest Connecticut Oncology Nursing Society Local Chapter Meeting. New Haven, CT.
- Davies, M.** (September, 2006) *Introduction to Oncology*. Yale Clinical Research Services. Yale Cancer Center. New Haven, CT.
- Davies, M.** (July, 2007) *Advances in the Treatment of Early Stage Breast Cancer*. South Boston Oncology Nursing Society Chapter Meeting. Kingston, MA.
- Davies, M.** (May, 2006) *Strategies for Management of Breast Cancer*. Oncology Nursing Society International Congress. Pre-Congress Session. Boston, MA.
- Davies, M.** (May, 2005) *Management of Complex Medical Problems in the Oncology Patient: COPD*. Oncology Nursing Society International Congress. Orlando, FL.
- Davies, M.** (January, 2005) *Breaking the Barriers: Clinical Trials Participation of Minority Populations*. Greater Las Vegas Oncology Seminar. Nevada Cancer Institute. Las Vegas, NV.
- Davies, M.** (November, 2004) *Importance of Clinical Trials Participation to Advancement of Cancer Care*. Southern Nevada Oncology Nursing Society Chapter Meeting. Las Vegas, NV.
- Davies, M.** (May, 2004) *Management of Complex Medical Problems in the Oncology Patient: Thyroid Dysfunction, Adrenal Dysfunction and Diabetes Mellitus*. Oncology Nursing Society International Congress. Anaheim, CA.
- Davies, M.** (March, 2004) *Blood Cell Counts & Fighting Fatigue*. Connecticut Chapter of the Leukemia & Lymphoma Society Lecture Series. New Haven, CT.
- Davies, M.** (September, 2003) *New Directions in Lung Cancer: Managing side effects of new therapies*. Southwestern Connecticut Oncology Nursing Society Chapter Presentation. Greenwich, CT.
- Davies, M.** (August, 2003) *Etiology and Treatment of Anemia and Cognitive Dysfunction in the Geriatric Oncology Patient*. Greater New Haven Oncology Nursing. New Haven, CT.
- Davies, M.** (July, 2003) *New Advances in the First Line Treatment of NSCLC*. Praxair Cancer Center. Westport, CT.
- Davies, M.** (July, 2003) *Taxotere in the Nursing Arena*. Yale Comprehensive Cancer Center. New Haven, CT.
- Davies, M.** (June, 2003) *The Treatment of NSCLC in the Elderly*. Greater New Haven Oncology Nursing. New Haven, CT.
- Davies, M.** (May, 2003) *Thromboembolic Complications in the Cancer Patient*. Advanced Oncology Nursing Instructional Session. Oncology Nursing Society Annual International Congress. Denver, CO.
- Davies, M.** (March 2003) *Anemia in Lung Cancer*. Central Massachusetts Oncology Nursing Society Chapter Meeting. Agawam, MA.
- Davies, M.** (February, 2003) *Fatigue: Managing the Burden of Cancer Therapy*. Lunch and Learn, Community Lecture Series. Yale Comprehensive Cancer Center. New Haven, CT.

**Multimedia Presentations**

Thompson, J. & **Davies, M.** (June 22, 2020). *Caring for Patients Treated with Immune Checkpoint Inhibitors: Guidance and Resources for Nurses and Pharmacists*. Clinical Care Options (CCO). Live West Coast & Enduring CME Webinar.

**Davies, M.** (June 10, 2020). *Maximizing the Benefits and Minimizing the Risks of Cancer Immunotherapies in Everyday Oncology Practice: Need-to-Know Information and practical Guidance for Oncology Nurses*. PeerView CME. Live & Enduring CME Webinar.

**Davies, M.** & Andrews, S. (May 19, 2020). *Caring for Patients Treated with Immune Checkpoint Inhibitors: Guidance and Resources for Nurses and Pharmacists*. Clinical Care Options (CCO). Live Southern & Enduring CME Webinar.

Thompson, J. & **Davies, M.** (May 5, 2020). *Caring for Patients Treated with Immune Checkpoint Inhibitors: Guidance and Resources for Nurses and Pharmacists*. Clinical Care Options (CCO). Live Northeast & Enduring CME Webinar.

**Davies, M.** (April 4, 2019). *Town Hall on COVID-19 and the Impact on Cancer Patients*. Axiom Healthcare Strategies. Live & Enduring Webinar.

**Davies, M.**, Rohan, K., & Charalambous A. (June 17, 2019). *Multidisciplinary Management of Immune-Mediated Adverse Events in Lung Cancer*. International Association for the Study of Lung Cancer (IASLC) Webinar Series Live & Enduring.

**Davies, M.** (October, 2018). *IO Essential videos for Patients*. (Lung Cancer, Shortness of breath-potential causes, adrenal insufficiency-management). AIM with Immunotherapy Foundation. Immuno-Oncology Essentials website. <https://aimwithimmunotherapy.org>

**Davies, M.** (October, 2018). *IO Essential videos for HCPs* (Hypophysitis management, adrenal insufficiency, pneumonitis management, shortness of breath management, Nephritis management, headache triage, myalgias/arthralgias, ocular issues) AIM with Immunotherapy Foundation. Immuno-Oncology Essentials website. <https://aimwithimmunotherapy.org>

**Davies, M.** (September, 2017). *Managing Toxicities of Newer Agents*. National Comprehensive Cancer Network (NCCN) Lung Cancer Congress Series. Baltimore, MD.

**Davies, M.** (March, 2017). *Management of Immune-related Adverse Events in Patients with NSCLC*. Live Webinar. ICLIO Immunotherapy in Lung Cancer Series. Institute for Clinical Immuno-Oncology (ICLIO)& The Association of Community Cancer Centers (ACCC).

**Davies, M.** (March, 2016). *Toxicities Related to Immunotherapies*. Live Webinar. NCCN Immunotherapies in Cancer Series. National Comprehensive Cancer Network® (NCCN).

Fidias, P., **Davies, M.**, & West, H., (2016). *“Defining Patient-Centered Care in an Era of Personalized Medicine: Spotlight on Advanced NSCLC”*. Medscape Education.

Fidias, P., **Davies, M.**, & Eaby-Sandy, B., (2016). *“Clinical Considerations in the management of EGFR-*

*Mutated Advanced NSCLC*". Medscape Education. <http://www.medscape.org/viewarticle/>

Bonomi, P., **Davies, M.**, Ettnger, D., Gralla, R., Kim, E., Koeller, J., Langer, C., & Wakelee, H., (2016). "Weight Loss in Patients with Lung Cancer: Current and emerging strategies to manage loss of appetite, sarcopenia, cachexia, and other problems and manifestations. BMLI. Web-Based CME & CE certified multimedia activity. <https://www.bmli.com/enduring/weightloss/>

**Davies, M.** (2015). "New modalities of cancer treatment for NSCLC: focus on immunotherapy". Video Abstract. <https://www.youtube.com/watch?v=9N7wOQ2GZGs>

Rivzi, N.A. & **Davies, M.** (2015). *Principles and Application of Immunotherapy in Cancer (PAIC)*. Webinar Series. inPractice Clinical Care Options.

**Davies, M.** (2015). *Managing Immunotherapy Side Effects, Parts 1 & 2*. Podcasts. Global Resource for Advancing Cancer Care (GRACE). <http://cancergrace.org/cancer-treatments/tag/marianne-davies/>

Brahmer, JR., Lipson, E.J., & **Davies, M.**, (2014). *Advancing the Understanding of Immuno-Oncology: Current Consensus and Future Directions in Targeting Immune Checkpoints in Solid Tumors*. PeerView inExchange. Web-Based CME/CNE/CPE-certified multimedia activity. <http://www.peerviewpress.com/advancing-understanding-immuno-oncology-current-consensus-and-future-directions-targeting-immune-checkpoints-solid-tumors>

### Commentaries, Editorials, Interviews

Hergert, J. (2020). Navigating Immune-Related Adverse Effects in Oncology. *OncLive*. Interview. August 12, 2020. [www.onclive.com/view/navigating-immune-related-adverse-effects-in-oncology](http://www.onclive.com/view/navigating-immune-related-adverse-effects-in-oncology).

**Davies, M.** (2019). "Five pillars for treating immune-related adverse events". *Oncology Nursing News*. Commentary. September, page 22.

Managing Immune-Related Toxicities in Patients with Lung Cancer. *The Oncology Nurse-APN/PA*. 10(2): 16. March 2017. [www.TheOncologyNurse.com](http://www.TheOncologyNurse.com).

Managing Immunotherapy Side Effects in Lung Cancer. *OncLiveTV*. November 2, 2015 [https://www.youtube.com/watch?v=WFQjaOC1\\_jc](https://www.youtube.com/watch?v=WFQjaOC1_jc).

Immunotherapy related side effects in lung cancer. *Cure®: Cancer Updates, Research & Education*. September 21, 2015. (Interview-World Lung Conference). <http://www.curetoday.com/cure-tv/marianne-davies-on-immunotherapy-related-side-effects-in-lung-cancer>  
<https://www.youtube.com/watch?v=DM1J-MoOnmA>

Setting Off a Smart Bomb. *Cure®: Cancer Updates, Research & Education®*. July, 15, 2015. (Interview). Pg 23.

Side Effects Associated with Immunotherapy. *OncLiveTV*. June 10, 2015. <https://www.youtube.com/watch?v=Utor16QsyfU>

Immunotherapy in Cancer Care: Educating patients about what to expect. *Oncology Nursing News*. July,

## Curriculum Vitae

2015. (Interview). Pg: 20-23.

Determining Patient Eligibility for Immunotherapy. OncLiveTV. April 25, 2015.  
<https://www.youtube.com/watch?v=qoM--czEnwg>

Chemotherapy Side Effects for Nurses and Patient. OncLiveTV. September 15, 2014.  
<https://www.youtube.com/watch?v=GZ-fxNixIcY>

Peer Review Process at Yale Cancer Center. OncLiveTV. July 10, 2014.  
<https://www.youtube.com/watch?v=V7ZYjg5Z6jo>

Evidence-Based Practice Council at Yale-New Haven Hospital. OncLiveTV. May 20, 2013.  
<https://www.youtube.com/watch?v=CYnXBkJ85ok>

### Professional Organizational Membership

1985-Present	American Nursing Association
1987- Present	Sigma Theta Tau, Delta Mu Chapter National Nursing Honor Society
1999- Present	Connecticut Nurse Practitioner Association
1998 - Present	Oncology Nursing Society
2013-Present	National Comprehensive Cancer Network (NCCN)
2013- Present	International Thoracic Oncology Nursing Forum (ITONF)
2013- Present	International Association for the Study of Lung Cancer (IASLC)
2014-Present	Advanced Practitioner Society for Hematology and Oncology (APSHO)
2014-Present	Society for Immunotherapy of Cancer (SITC)
2015-Present	International Association for the Study of Lung Cancer (IASLC) Nurse & Allied Health Professionals Committee
2016-Present	Association of Community Cancer Centers (ACCC) Institute for Clinical Immuno-Oncology (ICLIO)
2018-Present	AIM with Immunotherapy Foundation

### Professional Service

2018-present      **Advanced Practitioner Society for Hematology and Oncology (APSHO)**  
Mentorship Program-Mentor

## Curriculum Vitae

- Regional Lecture Series Developer: Lung Cancer & Immunotherapy
- 2018-Present      **AIM with Immunotherapy**  
Leadership Board
- 2018-present      **International Thoracic Oncology Nursing Forum (ITONF)**  
Steering Committee
- 2017-present      **National Comprehensive Cancer Center (NCCN)**  
Immunotherapy Guidelines Work Group  
Immunotherapy Toxicity Management Guidelines Task Force (invited expert)
- 2016-present      **Association of Community Cancer Centers (ACCC) Institute for Clinical  
Immuno-Oncology (ICLIO)**  
Lung Cancer Subcommittee
- 2017-present      **SITC-ACCC** “Advances in Cancer Immunotherapy-regional & national education  
program planner
- 2015-present      **Society for Immunotherapy of Cancer**  
2019-present      Annual Program Organizer (2020)  
2018-2019      34<sup>th</sup> Annual Meeting Organizer (2019)  
2017-present      Advances in Cancer Immunotherapy (ACI)-National planning committee  
2017-present      Immunotherapy Guidelines Task Force for Lung Cancer  
2017      Toxicity Management Workgroup (Content Expert) March 31,2017 Summit  
planner
- 2015-present      **International Association for the Study of Lung Cancer (IASLC)**  
2017-2020      IASLC Newsletter, Associate Editor  
2017-present      Education Committee  
2015-present      Nurse & Allied Health Professionals Committee:  
                         - Research Sub-Committee (2015-2017)  
                         -Education Sub-Committee (2015-2017)  
                         -Deputy Chair (2018-2019)
- 2018-present      **Journal of Cancer Survivorship**  
Journal Peer Reviewer
- 2015-present      **Journal of Palliative Care**  
Journal Peer Reviewer
- 2016-present      **Journal of the Advanced Practice Provider in Oncology**  
Journal Peer Reviewer
- 2014-Present      **Oncology Nurse Advisor**  
Editorial Board
- 2003-present      **Clinical Journal of Oncology Nursing**  
Journal Peer Review Board

## Curriculum Vitae

### **Oncology Nursing Society**

2017	Immuno-Oncology Think Tank (requested attendee as clinical expert) March 28, 2017.
2005	Scientific Program Committee Abstract Reviewer Annual Congress
2004	Coordinator Pre-Congress Instructional Session, Annual Congress, Anaheim, CA
2003-Present	Peer Review Board, <i>Clinical Journal of Oncology Nursing</i>
2003	Coordinator Instructional Session, Annual Congress, Denver,
2003	Board of Directors, Southwest Connecticut Chapter
2000-2016	Nurse Practitioner Special Interest Group
2000-2005	Coordinator Nurse Practitioner Mentorship Program
2000	Leadership Development Institute Fellow Project: Nurse Practitioner Mentorship Program
2000	Test Item Writer: OCN Certification Board
2000-2005	Clinical Trials Special Interest Group
2000-2002	Project Team Leader, PRISM Priority Symptom Management Professional Education Course Development Basic & Advance Courses
1999-2002	National Advisory Panel: Priority Symptom Management (PRISM)
1999-2002	Pain Management Special Interest Group

### **PCE NSCLC eNewsletter**

2017	Content Advisor
------	-----------------

### **Teaching and Mentoring:**

#### **Graduate Teaching Experience: Yale School of Nursing**

Spring 2020	N967 Quality & Safety in Healthcare Organizations
Fall/Spring 2019-20	N614a/b Clinical Practicum for Oncology Nurse Practitioner
Fall/Spring 2019-20	N613a/b Symptom Management of Oncology Nurse Practitioner
Spring 2019	N967 Quality & Safety in Healthcare Organizations
Fall/Spring 2018-19	N614a/b Clinical Practicum for Oncology Nurse Practitioner
Fall/Spring 2018-19	N613a/b Symptom Management for Oncology Nurse Practitioner
Spring 2018	N967 Quality & Safety in Healthcare Organizations
Spring 2018	N612b Principles of Advanced Oncology Practice Seminar
Fall 2017	N605 Transitions to Professional Practice
Summer 2017	N967 Theory & Application of Project Planning (DNP)
Spring 2017	N615b Principles of Advanced Oncology Nurse Practice
Fall/Spring 2016-18	N804a/b Clinical Practicum for Oncology Nurse Practitioners
Fall/Spring 2016-18	N803 a/b Symptom Management for Oncology Nurse Practitioners
Fall 2016	N717 Transitions to Professional Practice
Summer 2016	N967b Theory & Application of Project Planning (DNP)
Spring 2016	N615b Principles of Advanced Oncology Nursing Practice
Fall/Spring 2015-16	803a/b Symptom Management for Oncology Nurses
Fall/Spring 2015-16	804a/b Clinical Practicum for Oncology Nurse Practitioners
Fall 2015	N717 Transitions to Professional Practice
2014-16	819 Health Promotion and Disease Prevention in the Adult Continuum
Spring 2012-15	817b Professional Practice Issues for Adult Advanced Practice Nurses

## Curriculum Vitae

Fall 2012-14	554a Advanced Health Assessment Across the Lifespan
Spring 2013	704b Gerontology-Oncology for Oncology Nurse Practitioners
Fall 2011-12	610a Advanced Assessment
Fall/Spring 2005-06	803a/b Symptom Management for Oncology Nurses
Fall/Spring 2004-05	615a/b Oncology Principles and Practice
Fall/Spring 2003-04	804a/b Clinical Practicum for Oncology Nurse Practitioners

### Administration

2015-ongoing	Oncology Nurse Practitioner Concentration Coordinator
2014-2016	CPR/Certification Coordinator

### Lectures Given:

2020	Introduction to Oncology, N517. (January 17, 2020)
2019	Palliative Care Conversations
2019	Geriatric Oncology (Spring 2019)
2019	Introduction to Oncology, N517. (January, 2019)
2018	Geriatric Oncology (February 2018)
2018	End-of-Life Discussions and Care Planning, N786 & N788 (January 29, 2018)
2018	Introduction to Oncology, N517 (January 19, 2018)
2017	Geriatric Considerations in Oncology, N803 (January 23, 2017)
2017	Foundations of Oncology, N517a (January 10, 2017)
2015	Oncology 101 N517a
2015	Geriatric Oncology N803
2014	Advanced Assessment of HENT
2014	Immunizations Across the Lifespan
2014	Integrating Evidence Based Practice. N717 Context of Care
2014	Utilizing a Strategic Planning Approach to Transform Peer Review for Advanced Practice Nurses. DNP989b, Capstone Development
2013	Integrating Evidence Based Practice. N717 Contexts of Care
2013	Lung Cancer: Advances in Treatment
2013	Advances in Biologic Therapy in Solid Tumors
2012	Scope and Standards of AAPN Practice
2012	Credentialing, Privileges, Development of Collaborative Practice Agreements
2012	Lung Cancer Overview
2011	Management of Malignant Effusions
2011	Principles of Biologic Therapy
2011	Melanoma: State of Practice
2010	Lung Cancer State of Practice
2007	Management of Melanoma & Renal Cell Carcinomas
2004	Malignant Effusions
2003	Renal Problems in the Oncology Patient
2002	Lung Cancer: Implications for the Nurse Practitioner
2001	Lung Cancer
2001	Management of Renal Failure in the Oncology Patient.
2001	Peripheral Neuropathy
2001	Malignant Effusions
2000	Renal Dysfunction in the Oncology Patient
2000	Acute Renal Failure
2000	Respiratory Dysfunction

## Curriculum Vitae

2000 Fluid & Electrolyte Abnormalities

### Committees

2017-2019 YSN Commencement Awards Committee  
2019-2020 YSN Appointments & Promotions Committee (elected-at-large)  
2017-2018 YSN Appointments & Promotions Committee (elected-at-large)  
2016-2019 YSN & YNHH Collaborative Nursing Committee  
2016-2020 YSN Curriculum Committee  
Co-Chair 2017-2020  
2015-2016 YSN Safety Committee  
2015-2016 YSN Admissions Committee  
2014-2016 YSN/YSM IPE Health Promotion Committee  
2014-2016 YSN Simulation Committee

### Task Force

2015-2017 Clinical DNP exploration

### Clinical Preceptor

2015-present Oncology Nurse Practitioner students  
2005-2014 Oncology Nurse Practitioner students  
2001-2004 Oncology Nurse Practitioner students

### Yale New Haven Hospital, Yale Cancer Center

2019-present Immunotoxicity Oncology Board  
2019-2020 Universal Informed Consent Work-Group  
2019-2020 Protocol Review Committee  
2016-present Immunotherapy Working Group (Smilow Network)  
2014- 2015 Oral Chemotherapy Task Force  
2013-2014 EPIC Optimization Committee  
2011- 2016 YNHH Nursing Research & Evidenced Based Practice Committee  
Writing Network Co-Chair, 2012  
Journal Club Project, 2012- 2015  
2010-2011 EPIC- (EMR) Advisory Committee  
2010- Present Yale New Haven Hospital APRN Council  
Council Co-Chair, 2010- Present  
Peer Review Sub-Committee, 2010-Present  
Competency Based Orientation Committee, 2012- Present  
2009- 2015 Smilow Process & Operations Committee  
2009- Present Schwartz Center Rounds Planning Committee  
2009 -2010 Smilow Patient Safety and Quality Committee  
2002-2004 Logician (EMR) Advisory and Implementation Committee  
2002-2004 Medical Oncology Outpatient Leadership Committee  
2002-2004 Clinical Trial Nursing Course: Developer, Coordinator  
2000-2004 Oncology Advanced Practice Nursing Committee  
2000-2004 ACOS Pharmacy Committee, Chemotherapy Subcommittee  
1999-2014 YNHH Oncology Nursing Council  
Executive Committee  
Annual Program Committee 2005 - Present  
Council Co-Chair, 2010- Present  
Research Dissemination Sub-Group Chair, 2011-Present

## Curriculum Vitae

Journal Club Facilitator, 2011-present  
1999-2002 Yale-New Haven Hospital Advanced Practice Nursing Committee  
1999-2002 Yale Comprehensive Cancer Center Education Committee  
1999-2000 Outpatient Oncology Quality Assurance Committee  
1998-1999 Oncology Pain Management Committee  
1998-1999 Yale Comprehensive Cancer Center Community Outreach  
1998-1999 “The March”: National cancer awareness campaign.  
State & local planning committee; Clinic coordinator  
1997-1998 JCAHO Unit Coordinator  
1991-1998 Competency Based Orientation Committee  
1991-1998 Patient Assessment & Education Committee  
1987-1989 New product- equipment evaluation committee  
1985-1987 Cancer Nursing Education Seminar Presenter  
1985-1986 Yale New Haven Hospital Health Fairs  
1983-1987 Cancer Nursing Practice Seminar Committee  
1983-1987 Yale Comprehensive Cancer Nursing Committee